Evaluation of the Antitumor Potential of the Resorcinolic Lipid 3-Heptyl-3,4,6-trimethoxy-3H-isobenzofuran-1-one in Breast Cancer Cells
| Autor: | Roberto da Silva Gomes, Renata Trentim Perdomo, Edwin José Torres de Oliveira, Adilson Beatriz, Andréia Conceição Milan Brochado Antoniolli-Silva, Natan de David, Ana Paula Maluf Rabacow, Neimar Vitor, Rodrigo Juliano Oliveira, Alisson Meza, Maria de Fatima Cepa Matos, Dênis Pires de Lima |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Cancer Research
Programmed cell death Isobenzofuran Cell Survival medicine.medical_treatment Gene Expression Antineoplastic Agents Breast Neoplasms 010402 general chemistry 01 natural sciences 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Breast cancer Cell Line Tumor Gene expression medicine Cytotoxic T cell Humans 030212 general & internal medicine Viability assay Cell Death General Medicine medicine.disease Lipids 0104 chemical sciences G2 Phase Cell Cycle Checkpoints Oncology chemistry Cell culture Cancer research MCF-7 Cells Female Adjuvant |
| Zdroj: | Anticancer research. 38(8) |
| ISSN: | 1791-7530 |
| Popis: | Background/aim In recent years, the search for new anticancer experimental agents derived from natural products or synthetic analogues, such as resorcinolic lipids, has received increased attention. The present study aimed to evaluate the antitumor potential, describe the cell death mechanism and the effects of 3-Heptyl-3,4,6-trimethoxy-3Hisobenzofuran-1-one (AMS35AA) in combination with different chemotherapeutic agents in the MCF-7 cell line. Materials and methods Analysis of cytotoxic, genotoxic, membrane integrity, cell death and gene expression induced by the compound was performed. Results The AMS35AA and its association with 5-FU demonstrated reduction of cell viability; increase of cell death; enhancement of genomic damage and accumulation of cells in G2/M phase. Conclusion AMS35AA has potential for breast cancer treatment since it is capable of exerting cytotoxic and cytostatic effects in a breast cell line and also could be an adjuvant in cancer therapy when combined with 5-FU. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|